Kathleen M. Buchheit

Kathleen M. Buchheit

Auto-generated profile, based on publicly available information

Kathleen M. Buchheit

Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
KBKathleen M. Buchheit
Kathleen M. Buchheit
KCKatherine N. Cahill
Katherine N. Cahill
HKHoward R. Katz
Howard R. Katz
KMKatherine C. Murphy
Katherine C. Murphy
CFChunli Feng
Chunli Feng
TLTanya M. Laidlaw
Tanya M. Laidlaw

2 October 2024 in Allergy
Verified
Journal Article
Open access
KBKathleen M. Buchheit
Kathleen M. Buchheit
DSDominick Shaw
Dominick Shaw
GCGeoffrey Chupp
Geoffrey Chupp
LLLauri Lehtimaki
Lauri Lehtimaki
Enrico HefflerEnrico Heffler
Enrico Heffler
PHPeter H Howarth
Peter H Howarth
Interleukin (IL)‐5 is the key cytokine in the maturation, activation, proliferation, migration and survival of eosinophils, which are key effector cells in many upper and lower airway diseases. Through its effects on eosinophils, IL‐5 indirectly contributes to various pathophysiological processes including tissue damage, repair and remodelling. Understanding the importance of IL‐5 in eosinophil‐associated diseases led to the development of anti‐IL‐5 therapies, which provide clinical benefits across a range of conditions. However, recent evidence suggests that eosinophil‐depletion alone may not account for all of the therapeutic effects of anti‐IL‐5 therapy and that IL‐5 may also contribute to disease independently of its effects on eosinophils. Indeed, evidence from ex vivo studies and targeted therapy in vivo demonstrates that IL‐5 and its inhibition affects a much broader range of cells beyond eosinophils, including epithelial cells, plasma cells, mast cells, basophils, neutrophils, type 2 innate lymphoid cells, T regulatory cells and fibroblasts. This review will provide an update on the evidence supporting the breadth of IL‐5 biology relevant to disease pathogenesis beyond eosinophil‐associated inflammation, where there is a need for additional insight, and the clinical implications of a more central role of IL‐5 in type 2 inflammation.

1 January 2016 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
PDF file
KBKathleen M. Buchheit
Kathleen M. Buchheit
TLTanya M. Laidlaw
Tanya M. Laidlaw
Buchheit KM, et al. Allergy Asthma Immunol Res. 2016 Jul;8(4):298-304. http://dx.doi.org/10.4168/aair.2016.8.4.298

22 February 2021 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
NBNicole Bavaro
Nicole Bavaro
DGDeborah Gakpo
Deborah Gakpo
AMAnisha Mittal
Anisha Mittal
JBJillian C. Bensko
Jillian C. Bensko
TLTanya M. Laidlaw
Tanya M. Laidlaw
KBKathleen M. Buchheit
Kathleen M. Buchheit

23 March 2025 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
RKRadomir Kratchmarov
Radomir Kratchmarov
TDTiffany Dharia
Tiffany Dharia
KBKathleen Buchheit
Kathleen Buchheit

5 February 2022 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Closed access
JMJyotsna Mullur
Jyotsna Mullur
CSCamille M. Steger
Camille M. Steger
DGDeborah Gakpo
Deborah Gakpo
JBJillian C. Bensko
Jillian C. Bensko
RMRie Maurer
Rie Maurer
KBKathleen M. Buchheit
Kathleen M. Buchheit